- Home
- SCNI vs CERO Comparison
SCNI vs CERO Comparison
Compare SCNI & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- CERO
- Stock Information
- Founded
- SCNI 2003
- CERO 2017
- Country
- SCNI Israel
- CERO United States
- Employees
- SCNI N/A
- CERO N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- CERO
- Sector
- SCNI Health Care
- CERO
- Exchange
- SCNI Nasdaq
- CERO Nasdaq
- Market Cap
- SCNI 3.2M
- CERO 3.5M
- IPO Year
- SCNI N/A
- CERO N/A
- Fundamental
- Price
- SCNI $2.47
- CERO $9.93
- Analyst Decision
- SCNI
- CERO Strong Buy
- Analyst Count
- SCNI 0
- CERO 2
- Target Price
- SCNI N/A
- CERO $45.00
- AVG Volume (30 Days)
- SCNI 1.1M
- CERO 3.3M
- Earning Date
- SCNI 08-14-2025
- CERO 08-13-2025
- Dividend Yield
- SCNI N/A
- CERO N/A
- EPS Growth
- SCNI N/A
- CERO N/A
- EPS
- SCNI N/A
- CERO N/A
- Revenue
- SCNI $658,000.00
- CERO N/A
- Revenue This Year
- SCNI N/A
- CERO N/A
- Revenue Next Year
- SCNI N/A
- CERO N/A
- P/E Ratio
- SCNI N/A
- CERO N/A
- Revenue Growth
- SCNI N/A
- CERO N/A
- 52 Week Low
- SCNI $1.90
- CERO $6.71
- 52 Week High
- SCNI $8.92
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- SCNI 49.52
- CERO 50.09
- Support Level
- SCNI $2.15
- CERO $8.12
- Resistance Level
- SCNI $2.70
- CERO $13.14
- Average True Range (ATR)
- SCNI 0.22
- CERO 2.83
- MACD
- SCNI 0.01
- CERO 0.39
- Stochastic Oscillator
- SCNI 32.99
- CERO 19.58
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.